A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.
Jason Mark RedmanYo-Ting TsaiBenjamin A WeinbergRenee N DonahueShruti U GandhyMargaret E Gatti-MaysHoussein Abdul SaterMarijo BilusicLisa M CordesSeth M SteinbergJennifer L MarteCaroline JochemsSunnie S KimJohn L MarshallSheri McMahonErica RedmondJeffrey SchlomJames L GulleyJulius StraussPublished in: The oncologist (2022)
SOC + IO generated multifunctional MUC1- and brachyury-specific CD4+/CD8+ T cells despite concurrent chemotherapy. Although a tumor-directed immune response is necessary for T-cell-mediated antitumor activity, it was not sufficient to improve PFS. Adding agents that increase the number and function of effector cells may be required for clinical benefit.
Keyphrases
- metastatic colorectal cancer
- immune response
- induced apoptosis
- locally advanced
- dendritic cells
- cell cycle arrest
- drug delivery
- regulatory t cells
- open label
- endoplasmic reticulum stress
- randomized controlled trial
- cancer therapy
- cell death
- signaling pathway
- oxidative stress
- cell proliferation
- inflammatory response